China Proposes ICH E6(R3) Annex 2 Compliance for Clinical Trials from 2027

On August 10, 2026, China’s Center for Food and Drug Inspection (CFDI) published for public consultation a Chinese translation of ICH E6(R3) Annex 2 together with proposed implementation recommendation. Under the proposal, clinical trials initiated in China from January 1, 2027, would apply Annex 2.

For global drug developers, the proposal could bring China closer to a long-sought goal: greater consistency in clinical trial operations across major international markets. However, that alignment will not necessarily mean that global trial models can be transferred directly to China. Existing China-specific requirements relating to data governance, human genetic resources (HGR), and clinical site oversight will also need to be considered when implementing the international standard locally.

With a public consultation open for one month from August 10, 2026, sponsors have an opportunity to submit feedback and assess how the proposed implementation approach could affect planned and ongoing China clinical development activities.

Global Alignment vs. Local Reality

The CFDI's proposal reflects a clear drive to align China’s Good Clinical Practice (GCP) framework with ongoing ICH developments. Annex 2 addresses decentralized clinical trial (DCT) approaches, digital health technologies (DHTs), risk-based quality management (RBQM), and data integrity considerations.

This alignment could simplify the development and execution of global studies by supporting greater consistency in protocols, technology, and quality management across ICH markets.

The practical reality, however, is more complex. Implementation of Annex 2 in China will need to operate within the broader domestic regulatory environment. Requirements relating to data security, cross-border data handling, HGR, and clinical site oversight may introduce additional considerations compared with other markets.

In practice, sponsors may need to consider two broad operational approaches:

• The Unified Model: Global DCT tools, remote monitoring approaches, and standardized quality systems may be deployable in China with limited regional modification, allowing sponsors to operate largely from a common global framework.
• The Dual-Track Model: A framework where sponsors may need to build China-specific adaptations into global study designs to address applicable local regulatory requirements.

Which model emerges in practice will have significant implications for the cost, complexity, and speed of global clinical development.

Operational Areas Exposed by the 2027 Timeline

The proposed 2027 implementation date has important implications for MRCTs currently in planning. As Annex 2 addresses decentralized and technology-enabled trial approaches, sponsors should consider the potential operational impact early in the planning process:

• Digital Ecosystems & Data Governance: Annex 2 addresses the use of decentralized trial elements and digital technologies. When deploying global platforms in China, sponsors should also assess compliance with applicable Chinese data security, personal information protection, and cross-border data requirements.
• Quality Management Recalibration: Sponsors should assess whether existing risk-based quality management approaches require adjustment to reflect China-specific regulatory, site, operational requirements.
• Protocol Portability in MRCTs: Adding China sites to an active global program without considering applicable China-specific requirements early in development may result in additional protocol adaptations or delays in site activation.

Looking Ahead

Sponsors should consider the potential impact of the proposed framework before the requirements are finalized. With the public consultation underway and implementation proposed from January 1, 2027, sponsors planning trials involving decentralized elements, novel endpoints, or digital technologies should assess the potential implications for their China clinical development activities. Identifying potential areas of regulatory divergence early can help support smoother integration of China into global development programs.

Navigating this transition requires both proactive policy engagement and local operational expertise. Cisema works alongside pharmaceutical and biotech sponsors to provide the regulatory, clinical development, and quality management expertise needed to navigate these developments and prepare for evolving clinical trial frameworks across Asia.

To evaluate how the ICH E6(R3) Annex 2 transition could affect your global trial pipeline or to discuss support for the consultation process, contact Cisema today.

Further Information

• Explore Cisema’s services for pharmaceutical consulting in Asia-Pacific.

References

• Notice on the Public Solicitation of Chinese Translation Versions and Implementation Suggestions for ICH "E6(R3): Technical Guidelines for Good Manufacturing Practice in Drug Clinical Trials (GCP)" Annex 2